Inhibikase Therapeutics, a clinical-stage pharmaceutical company focused on developing protein kinase inhibitor therapeutics for Parkinson’s disease and related disorders, has announced that it will release its financial results for the second quarter of 2023 on August 14, 2023. The company will also provide a corporate update during a conference call and webcast on August 15, 2023.
Inhibikase Therapeutics is committed to finding therapeutic solutions that can modify the course of Parkinson’s disease, as well as other diseases associated with Abelson Tyrosine Kinases. The company’s lead program, IkT-148009, which is an Abelson Tyrosine Kinase inhibitor, aims to treat Parkinson’s disease both inside and outside the brain, along with other diseases linked to Abelson Tyrosine Kinases.
The conference call discussing the financial results and corporate update can be accessed by dialing 1-833-816-1414 (United States) or 1-412-317-0506 (International) using the conference code 7774190. Additionally, a live webcast will be available on the company’s website, www.inhibikase.com, or through the provided link. The webcast will be archived on the website for approximately 90 days following the event.
Inhibikase Therapeutics’ multi-therapeutic pipeline includes research and development efforts focused on neurodegeneration and Parkinson’s-related disorders of the brain and GI tract. The company is also exploring drug delivery technologies for kinase inhibitors, such as IkT-001Pro, which is a prodrug of the anticancer agent imatinib mesylate that aims to minimize on-dosing side-effects and provide a better patient experience.
Headquartered in Atlanta, Georgia, Inhibikase Therapeutics operates with offices located in Boston, Massachusetts. The company leverages various communication channels, including its investor relations website, press releases, SEC filings, public conference calls, webcasts, Twitter, Facebook, LinkedIn, and YouTube, to disseminate material financial information, disclose relevant information, and fulfill its disclosure obligations under Regulation FD.
It is crucial for companies like Inhibikase Therapeutics to provide updates to investors and the public, allowing stakeholders to stay informed about the latest advancements, financial performance, and research initiatives. As the conference call and webcast approach, interested individuals are encouraged to access the designated channels to gain insights into Inhibikase Therapeutics’ progress and future prospects in the field of Parkinson’s disease therapeutics.
